JNK1/2/3 (phospho-T183/Y185) polyclonal Antibody | BS4322

JNK1/2/3 (phospho-T183/Y185) polyclonal Antibody | BS4322 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IF IHC

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200

Background: The human JNK1 (PRKM8, SAPK1, MAPK8) gene maps to chromosome 10q11.22 and shares 83% amino acid identity with JNK2. JNK1 is necessary for normal activation and differentiation of CD4 helper T (TH) cells into TH1 and TH2 effector cells. Capsaicin activates JNK1 and p38 in Ras-transformed human breast epithelial cells. Nitrogen oxides (NOx) upregulate JNK1 in addition to c-Fos, c-Jun and other signaling kinases, including MEKK1 and p38. JNK3 (MK10, MAPK10, PRKM10) is activated by pro-inflammatory cytokines and environmental stresss by phosphorylating transcription factors such as c-Jun and ATF2. This is important for AP-1 transcriptional activity regulation. JNK3 is crucial for neuronal apoptosis (stress-induced) .

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: p-JNK1/2/3 (T183/Y185) polyclonal Antibody detects endogenous levels of JNK1/2/3 protein only when phosphorylated at Thr183 and Tyr185.

Molecular Weight: ~ 46,54 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: JNK 46; JNK 55; JNK; JNK1; JNK1A2; JNK2; JNK21B1/2; JNK2ALPHA; JNK2B; JNK2BETA; JNK3; JNK3A; MAP kinase 8; MAP kinase 9; MAP kinase p49 3F12; MAPK 8; MAPK 9; MAPK10; MAPK8; MAPK9; MGC50974; Mitogen activated protein kinase 10; Mitogen activated protein kinase 8; Mitogen activated protein kinase 9

Immunogen: Synthetic phosphopeptide derived from human JNK1 around the phosphorylation site of Threonine 183 and Tyrosine 185.

Conjugate: Unconjugated

Modification: Phosphorylation

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: PI3K AKT signaling,Translational Contral elF4 and p70 S6 Kinase,MTOR signaling,